Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis

Shahrokh F. Shariat, Douglas S. Scherr, Amit Gupta, Fernando J. Bianco, Pierre I. Karakiewicz, Ilia S. Zeltser, David B. Samadi, Ardavan Akhavan

Research output: Contribution to journalArticle

Abstract

The introduction and widespread adoption of PSA has revolutionized the way prostate cancer is diagnosed and treated. However, the use of PSA has also led to over-diagnosis and overtreatment of prostate cancer resulting in controversy about its use for screening. PSA also has limited predictive accuracy for predicting outcomes after treatment and for making clinical decisions about adjuvant and salvage therapies. Hence, there is an urgent need for novel biomarkers to supplement PSA for detection and management of prostate cancer. Despite the progress in developing new biomarkers, several obstacles remain before such biomarkers can be clinically used. These challenges include analytical and regulatory barriers, issues with study design and data analysis that lead to lack of reproducibility of promising results, and the lack of large scale trials to adequately assess the utility of promising biomarkers. In this article we discuss the challenges in biomarker research and the statistical considerations for biomarker evaluation. There is a plethora of promising blood and urine based biomarkers. For the purpose of this review, we focus on PSA derived forms, human kallikrein 2, Early Prostate Cancer Antigen, Transforming Growth Factor-Beta 1 and Interleukin-6, Endoglin, PCA3, AMACR and ETS Gene Fusions. These biomarkers have shown promise in early studies and are at various stages of development. However, in the future it is very likely that a panel of biomarkers will be used to achieve sufficient degree of certainty in order to guide clinical decisions. To be able to be used commercially such a panel will have to answer clinically relevant questions in a simple and cost-effective way.

Original languageEnglish (US)
Pages (from-to)681-694
Number of pages14
JournalArchivos Espanoles de Urologia
Volume64
Issue number8
StatePublished - Oct 2011
Externally publishedYes

Fingerprint

Neoplasm Staging
Prostatic Neoplasms
Biomarkers
Tissue Kallikreins
Salvage Therapy
Gene Fusion
Reproducibility of Results
Transforming Growth Factor beta
Interleukin-6
Urine
Antigens
Costs and Cost Analysis

Keywords

  • Diagnosis
  • Molecular markers
  • Prognosis
  • Prostate neoplasms
  • Prostate specific antigen
  • Staging

ASJC Scopus subject areas

  • Urology

Cite this

Shariat, S. F., Scherr, D. S., Gupta, A., Bianco, F. J., Karakiewicz, P. I., Zeltser, I. S., ... Akhavan, A. (2011). Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. Archivos Espanoles de Urologia, 64(8), 681-694.

Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. / Shariat, Shahrokh F.; Scherr, Douglas S.; Gupta, Amit; Bianco, Fernando J.; Karakiewicz, Pierre I.; Zeltser, Ilia S.; Samadi, David B.; Akhavan, Ardavan.

In: Archivos Espanoles de Urologia, Vol. 64, No. 8, 10.2011, p. 681-694.

Research output: Contribution to journalArticle

Shariat, SF, Scherr, DS, Gupta, A, Bianco, FJ, Karakiewicz, PI, Zeltser, IS, Samadi, DB & Akhavan, A 2011, 'Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis', Archivos Espanoles de Urologia, vol. 64, no. 8, pp. 681-694.
Shariat SF, Scherr DS, Gupta A, Bianco FJ, Karakiewicz PI, Zeltser IS et al. Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. Archivos Espanoles de Urologia. 2011 Oct;64(8):681-694.
Shariat, Shahrokh F. ; Scherr, Douglas S. ; Gupta, Amit ; Bianco, Fernando J. ; Karakiewicz, Pierre I. ; Zeltser, Ilia S. ; Samadi, David B. ; Akhavan, Ardavan. / Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. In: Archivos Espanoles de Urologia. 2011 ; Vol. 64, No. 8. pp. 681-694.
@article{d264a852876949788078c5ef7a5f030b,
title = "Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis",
abstract = "The introduction and widespread adoption of PSA has revolutionized the way prostate cancer is diagnosed and treated. However, the use of PSA has also led to over-diagnosis and overtreatment of prostate cancer resulting in controversy about its use for screening. PSA also has limited predictive accuracy for predicting outcomes after treatment and for making clinical decisions about adjuvant and salvage therapies. Hence, there is an urgent need for novel biomarkers to supplement PSA for detection and management of prostate cancer. Despite the progress in developing new biomarkers, several obstacles remain before such biomarkers can be clinically used. These challenges include analytical and regulatory barriers, issues with study design and data analysis that lead to lack of reproducibility of promising results, and the lack of large scale trials to adequately assess the utility of promising biomarkers. In this article we discuss the challenges in biomarker research and the statistical considerations for biomarker evaluation. There is a plethora of promising blood and urine based biomarkers. For the purpose of this review, we focus on PSA derived forms, human kallikrein 2, Early Prostate Cancer Antigen, Transforming Growth Factor-Beta 1 and Interleukin-6, Endoglin, PCA3, AMACR and ETS Gene Fusions. These biomarkers have shown promise in early studies and are at various stages of development. However, in the future it is very likely that a panel of biomarkers will be used to achieve sufficient degree of certainty in order to guide clinical decisions. To be able to be used commercially such a panel will have to answer clinically relevant questions in a simple and cost-effective way.",
keywords = "Diagnosis, Molecular markers, Prognosis, Prostate neoplasms, Prostate specific antigen, Staging",
author = "Shariat, {Shahrokh F.} and Scherr, {Douglas S.} and Amit Gupta and Bianco, {Fernando J.} and Karakiewicz, {Pierre I.} and Zeltser, {Ilia S.} and Samadi, {David B.} and Ardavan Akhavan",
year = "2011",
month = "10",
language = "English (US)",
volume = "64",
pages = "681--694",
journal = "Archivos Espanoles de Urologia",
issn = "0004-0614",
publisher = "Iniestares, S.A.",
number = "8",

}

TY - JOUR

T1 - Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis

AU - Shariat, Shahrokh F.

AU - Scherr, Douglas S.

AU - Gupta, Amit

AU - Bianco, Fernando J.

AU - Karakiewicz, Pierre I.

AU - Zeltser, Ilia S.

AU - Samadi, David B.

AU - Akhavan, Ardavan

PY - 2011/10

Y1 - 2011/10

N2 - The introduction and widespread adoption of PSA has revolutionized the way prostate cancer is diagnosed and treated. However, the use of PSA has also led to over-diagnosis and overtreatment of prostate cancer resulting in controversy about its use for screening. PSA also has limited predictive accuracy for predicting outcomes after treatment and for making clinical decisions about adjuvant and salvage therapies. Hence, there is an urgent need for novel biomarkers to supplement PSA for detection and management of prostate cancer. Despite the progress in developing new biomarkers, several obstacles remain before such biomarkers can be clinically used. These challenges include analytical and regulatory barriers, issues with study design and data analysis that lead to lack of reproducibility of promising results, and the lack of large scale trials to adequately assess the utility of promising biomarkers. In this article we discuss the challenges in biomarker research and the statistical considerations for biomarker evaluation. There is a plethora of promising blood and urine based biomarkers. For the purpose of this review, we focus on PSA derived forms, human kallikrein 2, Early Prostate Cancer Antigen, Transforming Growth Factor-Beta 1 and Interleukin-6, Endoglin, PCA3, AMACR and ETS Gene Fusions. These biomarkers have shown promise in early studies and are at various stages of development. However, in the future it is very likely that a panel of biomarkers will be used to achieve sufficient degree of certainty in order to guide clinical decisions. To be able to be used commercially such a panel will have to answer clinically relevant questions in a simple and cost-effective way.

AB - The introduction and widespread adoption of PSA has revolutionized the way prostate cancer is diagnosed and treated. However, the use of PSA has also led to over-diagnosis and overtreatment of prostate cancer resulting in controversy about its use for screening. PSA also has limited predictive accuracy for predicting outcomes after treatment and for making clinical decisions about adjuvant and salvage therapies. Hence, there is an urgent need for novel biomarkers to supplement PSA for detection and management of prostate cancer. Despite the progress in developing new biomarkers, several obstacles remain before such biomarkers can be clinically used. These challenges include analytical and regulatory barriers, issues with study design and data analysis that lead to lack of reproducibility of promising results, and the lack of large scale trials to adequately assess the utility of promising biomarkers. In this article we discuss the challenges in biomarker research and the statistical considerations for biomarker evaluation. There is a plethora of promising blood and urine based biomarkers. For the purpose of this review, we focus on PSA derived forms, human kallikrein 2, Early Prostate Cancer Antigen, Transforming Growth Factor-Beta 1 and Interleukin-6, Endoglin, PCA3, AMACR and ETS Gene Fusions. These biomarkers have shown promise in early studies and are at various stages of development. However, in the future it is very likely that a panel of biomarkers will be used to achieve sufficient degree of certainty in order to guide clinical decisions. To be able to be used commercially such a panel will have to answer clinically relevant questions in a simple and cost-effective way.

KW - Diagnosis

KW - Molecular markers

KW - Prognosis

KW - Prostate neoplasms

KW - Prostate specific antigen

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=80054998435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054998435&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 681

EP - 694

JO - Archivos Espanoles de Urologia

JF - Archivos Espanoles de Urologia

SN - 0004-0614

IS - 8

ER -